UTHR FY 2022 Earnings Report — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

United Therapeutics CorporationUTHR

FY 2022 Earnings

Reported February 22, 2023

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2022	Prior Q	FY 2021	QoQ Change	YoY Change
Revenue	$1.9B	—	$1.7B	—	14.9%
Op. Income	$980M	—	$556M	—	76.2%
Gross Margin	92.4%	—	92.7%	—	-0.3pp
Net Margin	37.6%	—	28.2%	—	9.3pp
EPS (Diluted)	$15.00	—	$10.06	—	49.1%
Free Cash Flow	$664M	—	$477M	—	39.0%

Revenue Flow

Item	Amount
REVENUE	$1.9B
Cost of Revenue	$147M
GROSS PROFIT	$1.8B
R&D Expenses	$323M
Selling & Marketing	$71M
General & Administrative	$416M
SG&A Expenses	$487M
Other Expenses	$0
Operating Expenses	$810M
Cost & Expenses	$957M
OPERATING INCOME	$980M
Interest Income	$45M
Interest Expense	$32M
Other Income/Expenses	-$29M
INCOME BEFORE TAX	$951M
Income Tax Expense	$223M
Net Income from Continuing Ops	$727M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$727M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$727M
D&A	$51M
EBIT	$989M
EBITDA	$1.0B
EPS	$16
EPS Diluted	$15

Income Statement

Item	Amount
REVENUE	$1.9B
Cost of Revenue	$147M
GROSS PROFIT	$1.8B
R&D Expenses	$323M
Selling & Marketing	$71M
General & Administrative	$416M
SG&A Expenses	$487M
Other Expenses	$0
Operating Expenses	$810M
Cost & Expenses	$957M
OPERATING INCOME	$980M
Interest Income	$45M
Interest Expense	$32M
Other Income/Expenses	-$29M
INCOME BEFORE TAX	$951M
Income Tax Expense	$223M
Net Income from Continuing Ops	$727M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$727M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$727M
D&A	$51M
EBIT	$989M
EBITDA	$1.0B
EPS	$16
EPS Diluted	$15

Cash Flow Statement

Item	Amount
Net Income	$727M
Depreciation & Amortization	$51M
Stock-Based Compensation	$107M
Deferred Income Tax	$0
Other Non-Cash Items	$58M
Change in Working Capital	-$141M
OPERATING CASH FLOW	$803M
Capital Expenditure	-$139M
Acquisitions (Net)	-$2M
Purchases of Investments	-$1.7B
Sales/Maturities of Investments	$1.0B
Other Investing Activities	$4M
NET CASH FROM INVESTING	-$812M
Net Debt Issuance	$0
Common Stock Repurchased	-$11M
Common Dividends Paid	$0
Other Financing Activities	$87M
NET CASH FROM FINANCING	$75M
FREE CASH FLOW	$664M
Net Change in Cash	$66M

Balance Sheet

Item	Amount
Cash & Equivalents	$961M
Short-Term Investments	$1.9B
Net Receivables	$220M
Inventory	$102M
Other Current Assets	$219M
TOTAL CURRENT ASSETS	$3.4B
PP&E (Net)	$862M
Goodwill	$28M
Intangible Assets	$17M
Long-Term Investments	$1.3B
Tax Assets	$328M
Other Non-Current Assets	$114M
TOTAL NON-CURRENT ASSETS	$2.7B
TOTAL ASSETS	$6.0B
Account Payables	$4M
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$13M
TOTAL CURRENT LIABILITIES	$343M
Long-Term Debt	$800M
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$105M
TOTAL NON-CURRENT LIABILITIES	$905M
TOTAL LIABILITIES	$1.2B
Common Stock	$700.0K
Additional Paid-In Capital	$2.4B
Retained Earnings	$5.0B
Treasury Stock	-$2.6B
Accum. Other Comp. Income	-$56M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$4.8B
Minority Interest	$0
TOTAL EQUITY	$4.8B
TOTAL LIABILITIES & EQUITY	$6.0B
Total Debt	$800M
Net Debt	-$161M